Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 2,500,000 Shares

Knight Therapeutics Inc. (TSE:GUD - Get Free Report) insider Sime Armoyan sold 2,500,000 shares of the stock in a transaction dated Friday, March 21st. The stock was sold at an average price of C$6.30, for a total transaction of C$15,750,000.00.

Sime Armoyan also recently made the following trade(s):

• On Wednesday, March 19th, Sime Armoyan sold 550,000 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.20, for a total transaction of C$3,410,000.00.
• On Monday, March 17th, Sime Armoyan sold 92,200 shares of Knight Therapeutics stock. The shares were sold at an average price of C$6.15, for a total transaction of C$567,030.00.
• On Thursday, March 13th, Sime Armoyan sold 1,100 shares of Knight Therapeutics stock. The stock was sold at an average price of C$6.10, for a total value of C$6,710.00.
• On Tuesday, March 4th, Sime Armoyan acquired 17,600 shares of Knight Therapeutics stock. The shares were purchased at an average cost of C$5.48 per share, with a total value of C$96,488.48.

Knight Therapeutics Trading Up 1.3 %

TSE GUD traded up C$0.08 during mid-day trading on Friday, reaching C$6.08. 31,080 shares of the stock were exchanged, compared to its average volume of 70,358. The business's fifty day simple moving average is C$5.73 and its 200 day simple moving average is C$5.59. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The stock has a market capitalization of C$614.99 million, a PE ratio of -20.30, a PEG ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics Inc. has a 1-year low of C$5.09 and a 1-year high of C$6.45.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group cut Knight Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, March 21st. Research Capitl upgraded shares of Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 11th. Finally, Stifel Nicolaus upped their price target on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the company a "buy" rating in a report on Tuesday. One research analyst has rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of C$7.48.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.